|
1
|
Engelhardt M, Terpos E, Kleber M, Gay F,
Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, et
al: European Myeloma Network recommendations on the evaluation and
treatment of newly diagnosed patients with multiple myeloma.
Haematologica. 99:232–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu WZ and Brandwein SR: Inhibition of type
II collagen-induced arthritis in rats by triptolide. Int J
Immunopharmacol. 20:389–400. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang
Z, Thorne A, Lehman AJ, Tsang IK and Esdaile JM: A randomized
double blind, placebo controlled trial of topical Tripterygium
wilfordii in rheumatoid arthritis: Reanalysis using logistic
regression analysis. J Rheumatol. 30:465–467. 2003.PubMed/NCBI
|
|
4
|
Liu H, Liu ZH, Chen ZH, Yang JW and Li LS:
Triptolide: A potent inhibitor of NF-kappa B in T-lymphocytes. Acta
Pharmacol Sin. 21:782–786. 2000.PubMed/NCBI
|
|
5
|
Zhao G, Vaszar LT, Qiu D, Shi L and Kao
PN: Anti-inflammatory effects of triptolide in human bronchial
epithelial cells. Am J Physiol Lung Cell Mol Physiol.
279:L958–L966. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qiu D, Zhao G, Aoki Y, Shi L, Uyei A,
Nazarian S, Ng JC and Kao PN: Immunosuppressant PG490 (triptolide)
inhibits T-cell interleukin-2 expression at the level of
purine-box/nuclear factor of activated T-cells and NF-kappaB
transcriptional activation. J Biol Chem. 274:13443–13450. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhou HF, Niu DB, Xue B, Li FQ, Liu XY, He
QH, Wang XH and Wang XM: Triptolide inhibits TNF-alpha, IL-1 beta
and NO production in primary microglial cultures. Neuroreport.
14:1091–1095. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu KB, Liu ZH, Liu D and Li LS: Inhibition
of vascular endothelial growth factor expression and production by
triptolide. Planta Med. 68:368–369. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim JH and Park B: Triptolide blocks the
STAT3 signaling pathway through induction of protein tyrosine
phosphatase SHP-1 in multiple myeloma cells. Int J Mol Med.
40:1566–1572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Johnson SM, Wang X and Evers BM:
Triptolide inhibits proliferation and migration of colon cancer
cells by inhibition of cell cycle regulators and cytokine
receptors. J Surg Res. 168:197–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding J, Huang S, Wang Y, Tian Q, Zha R,
Shi H, Wang Q, Ge C, Chen T, Zhao Y, et al: Genome-wide screening
reveals that miR-195 targets the TNF-/NF-κB pathway by
down-regulating IκB kinase alpha and TAB3 in hepatocellular
carcinoma. Hepatology. 58:654–666. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Korde N, Kristinsson SY and Landgren O:
Monoclonal gammopathy of undetermined significance (MGUS) and
smoldering multiple myeloma (SMM): Novel biological insights and
development of early treatment strategies. Blood. 117:5573–5581.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buenrostro D, Mulcrone PL, Owens P and
Sterling JA: The bone microenvironment: A fertile soil for tumor
growth. Curr Osteoporos Rep. 14:151–158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zipori D: The hemopoietic stem cell niche
versus the microenvironment of the multiple myeloma-tumor
initiating cell. Cancer Microenviron. 3:15–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghobrial IM: Myeloma as a model for the
process of metastasis: Implications for therapy. Blood. 120:20–30.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wallace SR, Oken MM, Lunetta KL,
Panoskaltsis-Mortari A and Masellis AM: Abnormalities of bone
marrow mesenchymal cells in multiple myeloma patients. Cancer.
91:1219–1230. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Abe M: Development of the therapies
targeting the interaction of myeloma cells with its bone marrow
microenvironment. Rinsho Ketsueki. 54:522–532. 2013.(In Japanese).
PubMed/NCBI
|
|
18
|
Mizuno H, Kikuta J and Ishii M: Bone and
stem cells. Intravital imaging of bone marrow microenvironment.
Clin Calcium. 24:541–546. 2014.(In Japanese). PubMed/NCBI
|
|
19
|
Verger E, Salamero M and Conill C: Can
Karnofsky performance status be transformed to the Eastern
Cooperative Oncology Group score scoring scale and vice versa? Eur
J Cancer 28A. 1328–1330. 1992. View Article : Google Scholar
|
|
20
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International Myeloma Working Group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu Y, Ma L, Ma G, Jiang X and Zhao C:
Comparative study of human fetal and adult bone marrow derived
mesenchymal stem cells. Zhonghua Xue Ye Xue Za Zhi. 23:645–648.
2002.(In Chinese). PubMed/NCBI
|
|
23
|
Yinjun L, Jie J and Yungui W: Triptolide
inhibits transcription factor NF-kappaB and induces apoptosis of
multiple myeloma cells. Leuk Res. 29:99–105. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wen L, Chen Y, Zeng LL, Zhao F, Yi S, Yang
LJ, Zhang BP, Zhao J, Zhao ZC and Zhang C: Triptolide induces cell
apoptosis by targeting H3K4me3 and down-stream effector proteins in
KM3 multiple myeloma cells. Curr Pharm Biotechnol. 17:147–160.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen
R, Ling X, Plunkett W and Andreeff M: MRx102, a triptolide
derivative, has potent antileukemic activity in vitro and in a
murine model of AML. Leukemia. 26:443–450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sun L, Li H, Zhang L and Zhou H:
Anticancer properties of triptolide: Inhibition of tumor-associated
macrophages differentiation and cytokine production. FASEB J.
30:1193–1199. 2016.
|
|
27
|
Knoblich JA and Lehner CF: Synergistic
action of Drosophila cyclins A and B during the G2-M transition.
EMBO J. 12:65–74. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hung FM, Chen YL, Huang AC, Hsiao YP, Yang
JS, Chung MT, Chueh FS, Lu HF and Chung JG: Triptolide induces S
phase arrest via the inhibition of cyclin E and CDC25A and triggers
apoptosis via caspase- and mitochondrial-dependent signaling
pathways in A375.S2 human melanoma cells. Oncol Rep. 29:1053–1060.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Vallee S, WU J, Vu D, Sondek J and
Ghosh G: Inhibition of NF-kappaB activity by IkappaBbeta in
association with kappaB-Ras. Mol Cell Biol. 24:3048–3056. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Biswas DK, Shi Q, Baily S, Strickland I,
Ghosh S, Pardee AB and Iglehart JD: Activation of NF-kappa B in
human breast cancer specimens and its role in cell proliferation
and apoptosis. Proc Natl Acad Sci USA. 101:10137–10142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grosjean-Raillard J, Tailler M, Adès L,
Perfettini JL, Fabre C, Braun T, De Botton S, Fenaux P and Kroemer
G: ATM mediates constitutive NF-kappaB activation in high-risk
myelodysplastic syndrome and acute myeloid leukemia. Oncogene.
28:1099–1109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yun JM, Afaq F, Khan N and Mukhtar H:
Delphinidin, an anthocyanidin in pigmented fruits and vegetables,
induces apoptosis and cell cycle arrest in human colon cancer
HCT116 cells. Mol Carcinog. 48:260–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dutta J, Fan Y, Gupta N, Fan G and Gélinas
C: Current insights into the regulation of programmed cell death by
NF-kappaB. Oncogene. 25:6800–6816. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Munshi NC and Avet-Loiseau H: Genomics in
multiple myeloma. Clin Cancer Res. 17:1234–1242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hideshima T, Mitsiades C, Tonon G,
Richardson PG and Anderson KC: Understanding multiple myeloma
pathogenesis in the bone marrow to identify new therapeutic
targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mitsiades CS, Mitsiades NS, Munshi NC,
Richardson PG and Anderson KC: The role of the bone
microenvironment in the pathophysiology and therapeutic management
of multiple myeloma: Interplay of growth factors, their receptors
and stromal interactions. Eur J Cancer. 42:1564–1573. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Podar K, Chauhan D and Anderson KC: Bone
marrow microenvironment and the identification of new targets for
myeloma therapy. Leukemia. 23:10–24. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Basak GW, Srivastava AS, Malhotra R and
Carrier E: Multiple myeloma bone marrow niche. Curr Pharm
Biotechnol. 10:345–346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yasui H, Hideshima T, Richardson PG and
Anderson KC: Novel therapeutic strategies targeting growth factor
signalling cascades in multiple myeloma. Br J Haematol.
132:385–397. 2006.PubMed/NCBI
|
|
40
|
Podar K, Richardson PG, Hideshima T,
Chauhan D and Anderson KC: The malignant clone and the bone-marrow
environment. Best Pract Res Clin Haematol. 20:597–612. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Garcia-Gomez A, Sanchez-Guijo F, Del
Cañizo MC, San Miguel JF and Garayoa M: Multiple myeloma
mesenchymal stromal cells: Contribution to myeloma bone disease and
therapeutics. World J Stem Cells. 6:322–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma JX, Sun YL, Wang YQ, Wu HY, Jin J and
Yu XF: Triptolide induces apoptosis and inhibits the growth and
angiogenesis of human pancreatic cancer cells by downregulating
COX-2 and VEGF. Oncol Res. 20:359–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
